BioCryst shareholders approve 7M share increase to Stock Incentive Plan

BIOCRYST PHARMACEUTICALS INC

Incentive Plan approved with 119.8M for, 63.3M against, adding 7M shares to the Plan.
Directors Heggie, McKee, Stonehouse re-elected; each received >170M votes for.
Non-binding say-on-pay passed but 56.8M (31% of votes cast) voted against.
Ernst & Young ratified as 2026 auditor with 210.3M votes for, 7.2M against.
34.0M broker non-votes recorded on director elections, say-on-pay, and plan vote.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.